CareDx Inc.

**Signal Note: Deerfield Management Initiates $41.3M Position in CareDx (CDNA)** Deerfield's $41.3M entry into CDNA signals conviction in the company's organ transplant diagnostics platform, particularly its AlloMap heart transplant rejection monitoring test and expanding kidney transplant assays. The timing may reflect confidence in upcoming clinical validation data or reimbursement developments that could expand addressable market adoption beyond current penetration levels. As a generalist healthcare investor, Deerfield's initiation suggests improving visibility into CDNA's path to scale or margin expansion.